{"id":26041,"date":"2023-12-13T18:04:54","date_gmt":"2023-12-13T12:34:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26041"},"modified":"2024-09-17T17:01:51","modified_gmt":"2024-09-17T11:31:51","slug":"phase-1-2-bruin-study-of-pirtobrutinib","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib","title":{"rendered":"Pirtobrutinib Monotherapy: A Promising Beacon of Efficacy and Safety in Relapsed\/Refractory Follicular Lymphoma Patients"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>10th December 2023<\/td><\/tr>
Indications<\/td>Follicular Lymphoma<\/td><\/tr>
Abstract Number<\/td>3026<\/td><\/tr>
Abstract type<\/td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. <\/strong>Additionally, the median duration of response (DOR) reached 5.5 months during the study’s median follow-up period of 18.4 months. At the 16.8-month mark, the median progression-free survival (PFS) was calculated to be 5.8 months. Noteworthy is the fact that the median overall survival (OS) could not be estimated (NE) as of the 20.4-month median follow-up.<\/p>\n\n\n\n

In terms of safety, the most frequent grade \u22653 treatment-emergent adverse events (TEAEs) were infection, observed in 18.8% of cases (n=9), and neutropenia or decreased neutrophil count, reported in 14.6% of instances (n=7). Notably, only one patient (2.1%) experienced a treatment-related adverse event, specifically a rash, leading to the discontinuation of pirtobrutinib.<\/p>\n\n\n\n

KOL insights<\/strong><\/strong><\/h2>\n\n\n\n
\n

\u201cFL is a chronic, indolent, and incurable disease with frequent relapses. Unfortunately, survival outcomes decrease with each subsequent line of treatment. \u201cThere have been some data looking at the role of covalent BTK inhibitors in relapsed\/refractory FL; however the single-agent efficacy is overall limited, with an ORR of approximately 20% to 38%. We [accordingly explored] pirtobrutinib, a non-covalent BTK inhibitor, for patients with relapsed\/refractory FL.\u201d \u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The administration of pirtobrutinib as a standalone treatment demonstrated promising effectiveness and a manageable safety profile among a group of extensively treated individuals grappling with R\/R FL. These findings indicate that pirtobrutinib could serve as a clinically relevant and valuable option for patients contending with R\/R FL, offering a potential avenue for effective therapeutic intervention in this challenging clinical context.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 10th December 2023 Indications Follicular Lymphoma Abstract Number 3026 Abstract type Oral According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. Additionally, the median duration of response […]<\/p>\n","protected":false},"author":6,"featured_media":26045,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,21533,841,927,18834,18921],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-cancer-research","tag-cancer-treatment","tag-follicular-lymphoma","tag-hematology","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nPhase 1\/2 BRUIN Study of Pirtobrutinib in Follicular Lymphoma<\/title>\n<meta name=\"description\" content=\"Key results and insights from the Phase 1\/2 BRUIN Study of Pirtobrutinib in Relapsed\/Refractory Follicular Lymphoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 1\/2 BRUIN Study of Pirtobrutinib in Follicular Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Key results and insights from the Phase 1\/2 BRUIN Study of Pirtobrutinib in Relapsed\/Refractory Follicular Lymphoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T12:34:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:31:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180439\/phase-1-2-bruin-study-of-pirtobrutinib.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Phase 1\/2 BRUIN Study of Pirtobrutinib in Follicular Lymphoma","description":"Key results and insights from the Phase 1\/2 BRUIN Study of Pirtobrutinib in Relapsed\/Refractory Follicular Lymphoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib","og_locale":"en_US","og_type":"article","og_title":"Phase 1\/2 BRUIN Study of Pirtobrutinib in Follicular Lymphoma","og_description":"Key results and insights from the Phase 1\/2 BRUIN Study of Pirtobrutinib in Relapsed\/Refractory Follicular Lymphoma.","og_url":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-13T12:34:54+00:00","article_modified_time":"2024-09-17T11:31:51+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180439\/phase-1-2-bruin-study-of-pirtobrutinib.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib","url":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib","name":"Phase 1\/2 BRUIN Study of Pirtobrutinib in Follicular Lymphoma","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180439\/phase-1-2-bruin-study-of-pirtobrutinib.png","datePublished":"2023-12-13T12:34:54+00:00","dateModified":"2024-09-17T11:31:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Key results and insights from the Phase 1\/2 BRUIN Study of Pirtobrutinib in Relapsed\/Refractory Follicular Lymphoma.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/phase-1-2-bruin-study-of-pirtobrutinib#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180439\/phase-1-2-bruin-study-of-pirtobrutinib.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180439\/phase-1-2-bruin-study-of-pirtobrutinib.png","width":1200,"height":800,"caption":"Phase 1\/2 BRUIN Study of Pirtobrutinib"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180439\/phase-1-2-bruin-study-of-pirtobrutinib-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 13, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 13, 2023 6:04 pm","modified":"Updated on Sep 17, 2024 5:01 pm"},"featured_img_caption":"Phase 1\/2 BRUIN Study of Pirtobrutinib","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26041"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26041\/revisions"}],"predecessor-version":[{"id":29576,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26041\/revisions\/29576"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26045"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26041"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26041"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}